Allogeneic stem cell transplantation can be a curative treatment for hematological malignancies. After HLA-matched allogeneic stem cell transplantation, beneficial anti-tumor immunity as well as detrimental side-effects can develop due to donor-derived T-cells recognizing polymorphic peptides that are presented by HLA on patient cells. Polymorphic peptides on patient cells that are recognized b...

background: different studies have demonstrated that a small proportion of healthy individuals receiving the hepatitis b (hb) vaccine do not produce protective levels of anti-hb antibody, a phenomenon which could be linked to certain human leukocyte an-tigen (hla) class-ii alleles or haplotypes. objectives: the present study was under-taken to determine the frequency of hla class-ii alleles in ...

studies have shown that patients who do not produce donor specific and / or panel reactive anti-hla antibodies have a longer graft survival. the purpose of this study was to evaluate the posttransplant humoral immune response towards hla-class i antigens and the measurement of the serum creatinine levels which are used in monitoring posttransplant function of kidney. serum samples from 132 rena...

Immunohistochemical staining with monoclonal antibodies showed marked variations in the percentage of melanoma cells stained by anti-HLA Class I and anti-HLA Class II monoclonal antibodies among 48 locoregional metastases removed from 39 patients with malignant melanoma. On the other hand there was limited variation in the percentage of melanoma cells stained by anti-HLA antibodies in autologou...

The HLA class I genes are located within a 2-million-base pair (2-Mbp) region constituting the telomeric half of the human major histocompatibility complex. The large majority of the class I sequences, including the HLA-A, -E, -F, and -G genes, is found within the telomeric 1 Mbp. We report here the isolation and characterization of yeast artificial chromosome (YAC) clones that span a contiguou...

from 1996 to 2002, fifty three patients with major beta-thalassemia received allogeneic peripheral blood stem cell trans plantation (pbsct). median age was 6 years .twenty two were class i, 17 class ii and 14 class iii. all of the donors were hla-identical. conditioning regimen for class i and ii patients consisted of cyclophosphamide (cy) 50 mg/kg/day for 4 days + busulfan (bu) 3.5 mg/kg for 4...

Background: Anthropological studies based on highly polymorphic HLA genes pro-vide useful information for bone marrow donor registry, forensic medicine, disease as-sociation studies, as well as designing peptide vaccines against tumors, and infectious or autoimmune diseases. Objective: This study was designed to investigate the genetic relationship of Iranian Arabs and Jews using HLA-class II g...

Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL), ...

The classical class I human leukocyte antigens (HLA-A, -B, and -C) present allele-specific self- or pathogenic peptides originated by intracellular processing to CD8(+) immune effector cells. Even a single mismatch in the heavy chain (hc) of an HLA class I molecule can impact on the peptide binding profile. Since HLA class I molecules are highly polymorphic and most of their polymorphisms affec...